As patient demand for biological medicines increases, and to keep pace with changes in the pharmaceutical and healthcare landscapes, but also beyond, we believe the next edition of the conference will provide a meaningful opportunity to jump start the multistakeholder policy process, ensuring the European policy framework and Global regulatory system secure more biosimilar medicines development and equitable access.
